Darbepoetin Alfa (Aranesp) Market Report 2026

Darbepoetin Alfa (Aranesp) Market Overview

• Darbepoetin Alfa (Aranesp) market size has reached to $6.06 billion in 2025 • Expected to grow to $7.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% • Growth Driver: Rising Chronic Disease Burden Fuels Growth In Darbepoetin Alfa Market • Market Trend: Vafseo Expands Global Reach As Vadadustat Gains Approval In Australia • North America was the largest region in 2025.

What Is Covered Under Darbepoetin Alfa (Aranesp) Market?

Darbepoetin alfa (Aranesp) is a medication used to treat anemia brought on by chemotherapy and chronic kidney disease. It helps the bone marrow make more red blood cells. The main types of darbepoetin alfa (Aranesp) are epogen, procrit, aranesp, and others. Epogen refers to a synthetic version of a protein that aids in the body's production of red blood cells and is used to treat anemia, which is the body's shortage of red blood cells. These are distributed through various distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used in various applications such as patients with chronic kidney disease, patients with cancer, and others.

What Is The Darbepoetin Alfa (Aranesp) Market Growth Forecast?

The darbepoetin alfa (aranesp) market size is expected to see strong growth in the next few years. It will grow to $7.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growth in aging population, rising demand for long-acting anemia therapies, increasing adoption of biosimilars, improved anemia diagnosis rates, expansion in emerging healthcare markets. Major trends in the forecast period include rising use of long-acting erythropoiesis-stimulating agents, growing preference for biosimilars in anemia treatment, increasing anemia incidence in chronic kidney disease patients, expanded use in chemotherapy-induced anemia management, shift toward hospital-based specialty drug administration.

Global Darbepoetin Alfa (Aranesp) Market Segmentation

1) By Type: Epogen, Procrit, Aranesp, Other Types 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 3) By Application: Patients With Chronic Kidney Disease, Patients With Cancer, Other Applications Subsegments: 1) By Epogen: Standard Formulations, Enhanced Formulations 2) By Procrit: Standard Formulations, Biosimilars 3) By Aranesp: Single-Dose Vials, Multi-Dose Vials 4) By Other Types: Combination Therapies, Alternative Erythropoiesis-Stimulating Agents

What Is The Driver Of The Darbepoetin Alfa (Aranesp) Market?

The increase in the prevalence of chronic diseases is expected to propel the growth of the darbepoetin alfa market going forward. Chronic diseases are illnesses that persist for three months or more and can progressively worsen over time. Darbepoetin alfa (Aranesp) is used to manage complications associated with chronic diseases, such as chemotherapy-induced anemia in cancer patients, by stimulating red blood cell production and improving quality of life. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the darbepoetin alfa market.

Key Players In The Global Darbepoetin Alfa (Aranesp) Market

Major companies operating in the darbepoetin alfa (aranesp) market are Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Biocon Ltd., Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Kyowa Kirin Co. Ltd., Polifarma S.p.A.

Global Darbepoetin Alfa (Aranesp) Market Trends and Insights

Major companies operating in the darbepoetin alfa market are increasing their focus on introducing new medicines, such as Vafseo (vadadustat), to gain a competitive edge in the market. Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Vafseo is designed to treat anemia associated with chronic kidney disease. For instance, in September 2023, Akebia Therapeutics, a US-based biotechnology company, received approval from Australia's Therapeutic Goods Administration (TGA) for Vafseo in Australia. It is authorized for use in 36 countries, including Taiwan. The approval in Australia was based on the global Phase 3 clinical program of vadadustat, which demonstrated its effectiveness in treating anemia due to CKD in adults on chronic maintenance dialysis.

What Are Latest Mergers And Acquisitions In The Darbepoetin Alfa (Aranesp) Market?

In March 2025, Julphar, a UAE-based pharmaceutical company, formed a strategic licensing partnership with Dong-A ST, to launch an innovative biotechnology product, Darbepoetin Alfa, in the MENA region. With this partnership, Julphar would strengthen its biopharmaceutical portfolio by commercializing a biosimilar of Darbepoetin Alfa, expanding access to patients with anemia associated with chronic kidney disease. Dong-A ST is a South Korea-based biopharmaceutical company provides the darbepoetin alfa technology and expertise in erythropoiesis-stimulating agents, supporting the product’s development and regional launch.

Regional Insights

North America was the largest region in the darbepoetin alfa (Aranesp) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Darbepoetin Alfa (Aranesp) Market?

The darbepoetin alfa market consists of sales of Aranesp sure click, Aranesp albumin free, and Aranesp sing eject. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Darbepoetin Alfa (Aranesp) Market Report 2026?

The darbepoetin alfa (aranesp) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the darbepoetin alfa (aranesp) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.